Pharmacotherapies for Overeating and Obesity
- PMID: 23826512
- PMCID: PMC3697760
- DOI: 10.4172/2157-7412.1000131
Pharmacotherapies for Overeating and Obesity
Abstract
Obesity has become pandemic, and the annual cost in related illnesses and loss of productivity is already over $100 billion and rising. Research has shown that obesity can and does cause changes in behavior and in the brain itself that are very similar to changes caused by drugs of abuse. While food addiction is not the causal agent of all obesity, it is clear that many people no longer eat to survive, but instead survive to eat. This review considers the importance of the brain's reward system in food intake. The review also examines research developments and current treatments for obesity, including diet and exercise, psychotherapy, surgical interventions, and pharmacotherapies. Finally we discuss alterations in American society that are necessary for change to occur, and the diffculties therein.
Keywords: Brain reward circuitry; Dopamine; Obesity; Pharmacotherapies; Reward Deficiency Syndrome (RDS); Social change.
Conflict of interest statement
Kenneth Blum, PhD, has been awarded a number of global patents for Obesity treatment compounds. Mark Gold, MD, has US patents pending related to obesity treatment compounds. No other author has any conflict to report.
References
-
- Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Aff (Millwood) 2002;21:245–253. - PubMed
-
- Skidmore PM, Yarnell JW. The obesity epidemic: prospects for prevention. QJM. 2004;97:817–825. - PubMed
-
- NIDDK. Overweight and Obesity Statistics WIN: Weight-control Information Network. 2005.
-
- Avena NM, Gold MS. Food and addiction - sugars, fats and hedonic overeating. Addiction. 2011;106:1214–1215. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources